NEXT GENERATION MEDICINE™ THROUGH INTERROGATIVE BIOLOGY®, POWERED BY bAIcis®
BERG has embraced an industry-disrupting approach for advancing drug discovery and development that harnesses the power of artificial intelligence (AI), coupled with patient biology, to accelerate clinical identification and the pursuit of promising therapeutic targets to treat disease. BERG’s proprietary Interrogative Biology platform is the engine that drives our discovery innovation. By taking a biology-driven approach to mapping disease, researchers at BERG can decode and compare vast biological samples to identify and leverage biomarkers as a window into disease – eliminating much of the “guess-and-check” approach from drug discovery.
“We’re convinced that a comprehensive understanding of patient biology is the key to unlocking insights that will catalyze drug discovery for some of our most challenging and debilitating diseases. Through the identification of predictive and prognostic biomarkers of disease activity, we can more effectively personalize medicine, while advancing development programs faster and more cost-effectively.” – Niven R. Narain, Ph.D., Co-Founder, President & CEO of BERG